Why I’d buy Tristel plc and avoid Genus plc after HY results

Half-year results reveal two different stories with Tristel plc (LON: TSTL) and Genus plc (LON: GNS)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The market likes FTSE AIM company Tristel’s (LSE: TSTL) half-year report today. The shares are up more than 8% as I write, so the UK-based manufacturer of infection prevention and contamination control products must be doing something right.

Trading well and expansion overseas

Indeed, the headline figures are impressive with revenue up 22% compared to a year ago, adjusted earnings per share ticked 14% higher and the directors increased the interim dividend by 23%.

Tristel reckons its lead technology is a proprietary chlorine dioxide formulation, which the firm uses to addresses hospital infection prevention, control of contamination in critical environments, and veterinary practice infection prevention. I find the growth proposition compelling here as Tristel expands abroad with overseas sales up 45% and representing 43% of total sales.

In August, Tristel made an acquisition in Australia, which delivered positive trading results during the period, and according to chief executive Paul Swinney,  the company is making satisfactory progress with its planned entry into the North American hospital market. The potential for further growth seems huge.

Quality, growth and momentum

With the return on capital running at 17% or so, Tristel scores well on quality, growth and share-price momentum. However, you’ve got to pay up to own the shares. At today’s share price of 162p, the forward price-to-earning (P/E) ratio sits at just under 21 for the year to June 2018 and the forward yield is around 2.2%. Given the firm’s ongoing progress, I’d be happy to buy a few of the shares following today’s update.

But with FTSE 250 animal genetics company Genus (LSE: GNS) I’m more cautious. The firm’s headline figures today include adjusted earnings per share down 9% on a constant currency basis and net debt ballooning by 24%. The company says planned increases in research and development expenditure drove strategic progress but also contributed to a 10% decline in adjusted profit before tax. 

A rich valuation

Given the firm’s rich valuation, I think operational progress seems slow. At today’s 1,747p share price, the forward P/E rating for the year to June 2018 runs at just over 24 and the forward dividend yield is around 1.5%. City analysts following the company expect forward earnings to cover the payout around 2.8 times.

Over the last 10 years the share price has risen around 190% but the compound annual growth rate of normalised earnings, including forecasts for the next two years, runs at just 9%. I wonder if that growth rate justifies such a rich valuation.

That said, Genus operates in a defensive sector and cash generation is good, generally supporting and rising in line with profits. The firm’s return on capital runs around 9% and the operating profit margin at 15% or so. Perhaps the quality of the operation will keep the stock travelling with the momentum we’ve seen over the last few years. However, if it does, it will be without me aboard. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »